Pigmentary retinitis (pigment attack) is a hereditary disease of the retina, characterized by progressive deterioration of vision, which is associated with degeneration of photoreceptors, mainly rods, and subsequent decrease in the function of the visual analyzer. The main manifestations of the disease include night blindness, narrowing of the visual fields and, ultimately, possible blindness. Pigmentary retinitis can be caused by various gene mutations, which leads to metabolic disorders in the retina and degenerative processes that have a negative impact on vision.
History of the disease and interesting historical facts
Throughout history, retinitis pigmentosa has been studied by many scientists and doctors. The first descriptions of the symptoms of the disease date back to the 19th century. In 1857, Aldridge described cases of hereditary progressive deterioration of vision in his works. In 1910, the Italian ophthalmologist Giuseppe Verone noted the characteristic appearance of "pigment spots" on the fundus, which later became an important sign for diagnosing the disease. In the following decades, it was established that the disease can be transmitted by various types of inheritance, including autosomal dominant and autosomal recessive types.
Epidemiology
Epidemiological data indicate that the prevalence of retinitis pigmentosa ranges from 1:3000 to 1:5000 in the general population. This disease is observed in both men and women, but in some cases its manifestations may be more pronounced in men. In world practice, more than 200 genetic variants have been identified that can lead to the development of this disease, which makes it difficult to estimate the exact prevalence among different ethnic groups. According to one large study, approximately 30-50% patients with progressive retinitis pigmentosa also have concomitant neurological disorders.
Genetic predisposition to this disease
Retinitis pigmentosa is associated with mutations in more than 50 different genes. Among the most frequently implicated genes are RHO, USH2A, EYS, and RPGR. Mutations in these genes significantly affect photoreceptor function. For example, mutations in the RHO gene, which encodes rhodopsin, can cause early onset of the disease, while mutations in the USH2A gene often result in later onset and associated auditory dysfunction. Genetic predisposition to retinitis pigmentosa is confirmed by familial cases of the disease, with the risk of transmission from parents to children being about 50% in the case of autosomal dominant inheritance.
Risk factors for the development of this disease
Potential risk factors that contribute to the development of retinitis pigmentosa include:
- Heredity: A family history of retinitis pigmentosa significantly increases the risk of developing the disease in offspring.
- Environmental exposure: Exposure to certain chemicals, such as some pesticides and solvents, may be associated with retinal deterioration in susceptible individuals.
- Age: The older the patient, the higher the likelihood of disease progression.
There are not enough proven theories about the physiological factors that contribute to the development of retinitis pigmentosa; however, there are suggestions about the possible influence of serotonin and other neurotransmitters on photoreceptor function.
Diagnosis of this disease
The diagnosis of retinitis pigmentosa is based on a combination of clinical examination and additional research methods. The main symptoms of the disease include:
- Night blindness;
- Harvest reduction of visual fields;
- The appearance of blind spots on the retina;
- Decreased visual acuity over time.
Laboratory testing usually includes genetic testing to identify mutations associated with the disease. Radiological tests such as optical coherence tomography (OCT) can visualize changes in the retina and assess the health of the photoreceptors. Differential diagnosis should include other retinal diseases such as macular degeneration or chorioretinopathy.
Treatment
To date, treatment of retinitis pigmentosa remains mainly symptomatic, since the disease is progressive and there is currently no radical treatment:
- General treatment: includes supporting the patient's general condition, taking eye vitamins, especially vitamins A and E, which can slow down progression.
- Pharmacological treatment: There are currently no drugs that can stop photoreceptor degeneration, but some research is focused on using new therapies.
- Surgical treatment: In rare cases, retinal implantation or tissue grafting may be appropriate.
- Other treatments: Gene therapy and cell therapy are being explored, but these methods are in the early stages of clinical trials.
List of medications used to treat this disease
There are currently no specific medications approved for the treatment of retinitis pigmentosa, but some medications may be recommended to help maintain overall health:
- Vitamins A and E;
- Omega-3 polyunsaturated fatty acids;
- Antioxidants;
- Preparations that improve microcirculation.
Disease monitoring
Monitoring of patients with retinitis pigmentosa includes regular eye examinations to assess disease progression and possible complications. The prognosis for many patients is poor, with the possibility of complete vision loss. Complications may include secondary cataracts and other visual impairments requiring surgical intervention.
Age-related features of the disease
Retinitis pigmentosa can manifest itself at different ages. In childhood, the patient may experience manifestations of night blindness, while in more mature age, the syndrome progresses. In adolescence and young adulthood, patients may not realize the seriousness of the disease, but by maturity, vision loss becomes more noticeable. In older people, the risk of concomitant diseases, such as glaucoma, increases.
Questions and Answers
- What is retinitis pigmentosa?
Retinitis pigmentosa is a hereditary disease of the retina characterized by visual impairment and degeneration of photoreceptors, most often rods. - Can retinitis pigmentosa be inherited?
Yes, retinitis pigmentosa is usually a hereditary disease, with different patterns of inheritance. - What treatments are available for patients with retinitis pigmentosa?
At present, treatment is mainly symptomatic and includes support of the general condition, but there are no radically effective drugs. - What are the main symptoms of retinitis pigmentosa?
The main symptoms include night blindness, narrowing of the visual fields and, eventually, decreased visual acuity. - How is retinitis pigmentosa diagnosed?
Diagnosis is based on clinical examination, genetic testing, and imaging techniques such as optical coherence tomography.
